138 related articles for article (PubMed ID: 8872417)
1. An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. The Tacrine 970-6 Study Group.
Foster NL; Petersen RC; Gracon SI; Lewis K
Dementia; 1996; 7(5):260-6. PubMed ID: 8872417
[TBL] [Abstract][Full Text] [Related]
2. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
Chatellier G; Lacomblez L
BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
[TBL] [Abstract][Full Text] [Related]
3. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
Almkvist O; Jelic V; Amberla K; Hellström-Lindahl E; Meurling L; Nordberg A
Dement Geriatr Cogn Disord; 2001; 12(1):22-32. PubMed ID: 11125238
[TBL] [Abstract][Full Text] [Related]
4. The effect of tacrine and lecithin in Alzheimer's disease. A population pharmacodynamic analysis of five clinical trials.
Holford NH; Peace K
Eur J Clin Pharmacol; 1994; 47(1):17-23. PubMed ID: 7988619
[TBL] [Abstract][Full Text] [Related]
5. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study.
Gauthier S; Bouchard R; Lamontagne A; Bailey P; Bergman H; Ratner J; Tesfaye Y; Saint-Martin M; Bacher Y; Carrier L
N Engl J Med; 1990 May; 322(18):1272-6. PubMed ID: 2183056
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial.
Maltby N; Broe GA; Creasey H; Jorm AF; Christensen H; Brooks WS
BMJ; 1994 Apr; 308(6933):879-83. PubMed ID: 8173365
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease.
Farlow MR; Lahiri DK; Poirier J; Davignon J; Schneider L; Hui SL
Neurology; 1998 Mar; 50(3):669-77. PubMed ID: 9521254
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
[TBL] [Abstract][Full Text] [Related]
9. Tacrine in Alzheimer's disease.
Eagger SA; Levy R; Sahakian BJ
Lancet; 1991 Apr; 337(8748):989-92. PubMed ID: 1673209
[TBL] [Abstract][Full Text] [Related]
10. Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with Alzheimer's disease.
Perryman KM; Fitten LJ
Life Sci; 1993; 53(6):479-86. PubMed ID: 8341134
[TBL] [Abstract][Full Text] [Related]
11. Potential role for estrogen replacement in the treatment of Alzheimer's dementia.
Schneider LS; Farlow MR; Pogoda JM
Am J Med; 1997 Sep; 103(3A):46S-50S. PubMed ID: 9344406
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of tacrine hydrochloride (Cognex) in two parallel-group studies.
Gracon SI
Acta Neurol Scand Suppl; 1996; 165():114-22. PubMed ID: 8740998
[TBL] [Abstract][Full Text] [Related]
13. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
Zemlan FP
J Neural Transm (Vienna); 1996; 103(8-9):1105-16. PubMed ID: 9013398
[TBL] [Abstract][Full Text] [Related]
14. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease.
Schneider LS; Farlow MR; Henderson VW; Pogoda JM
Neurology; 1996 Jun; 46(6):1580-4. PubMed ID: 8649552
[TBL] [Abstract][Full Text] [Related]
15. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease.
Schneider LS; Olin JT; Pawluczyk S
Am J Psychiatry; 1993 Feb; 150(2):321-3. PubMed ID: 8422085
[TBL] [Abstract][Full Text] [Related]
16. Double-blind placebo-controlled study of velnacrine in Alzheimer's disease.
Zemlan FP; Keys M; Richter RW; Strub RL
Life Sci; 1996; 58(21):1823-32. PubMed ID: 8637408
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, placebo-controlled study of tacrine in Chinese patients with Alzheimer's disease.
Wong WJ; Liu HC; Fuh JL; Wang SJ; Hsu LC; Wang PN; Sheng WY
Dement Geriatr Cogn Disord; 1999; 10(4):289-94. PubMed ID: 10364647
[TBL] [Abstract][Full Text] [Related]
18. Tetrahydroaminoacridine and lecithin in the treatment of Alzheimer's disease. Effect on cognition, functioning in daily life, behavioural disturbances and burden experienced by the carers.
Weinstein HC; Teunisse S; van Gool WA
J Neurol; 1991 Feb; 238(1):34-8. PubMed ID: 2030370
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Antuono PG
Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
[TBL] [Abstract][Full Text] [Related]
20. Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease.
Schneider LS; Farlow M
Ann N Y Acad Sci; 1997 Sep; 826():317-22. PubMed ID: 9329702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]